The chemotherapy drug Abraxane may be more effective than Taxotere for women who have metastatic breast cancer, a company-funded study has found. Researchers say that Abraxane increased a patient's survival time by almost seven months when compared with Taxotere. The most potent dose in the 302 female participants appeared to be a weekly dose for three weeks, with a fourth week off. Experts say the study's results indicate that Abraxane may be a better first-line of treament for women whose...